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CASE1
AN INTEGRATED PILOT PROJECT UTILIZING AN INTERNAL
HTA PROCESSTO SET MEDICAL AND PAYMENT POLICY IN A
U.S. COMMERCIAL HEALTH PLAN
Watkins J1, Choudhury S1, Sturm L2, Bresnahan B3, Sullivan S3
1Premera Blue Cross, Mountlake Terrace,WA, USA; 2Formulary
Resources, LLC, Issaquah,WA, USA; 3University of Washington,
Seattle,WA, USA
Organization: Premera Blue Cross is a 1.6 million member
regional commercial health plan in the Paciﬁc Northwest.
Problem or Issue Addressed: Need to perform more rigorous
assessments of new medical technologies that present budgetary
and utilization management challenges to our health plan.
Goals: (1) Develop and demonstrate a health technology assess-
ment process for non-pharmacologic new medical technologies,
utilizing plan medical and pharmacy staff, students and contrac-
tors as reviewers, including economic evaluations where data are
available. (2) Apply these assessments to inform development of
speciﬁc medical necessity policies and payment policies and
implement the policy changes at Premera.
Outcomes items used in the decision: Clinical efﬁcacy/
effectiveness, safety, clinical utility and cost-effectiveness/cost-
utility (when sufﬁcient data were available).
Implementation Strategy: A cross-functional strategic planning
group of Premera staff, with advice from University of Wash-
ington faculty, designed a comprehensive process to assess the
value of new medical technologies (medical devices, diagnostics
and novel procedures using existing devices) and apply the
results to policy development. To strengthen our business case,
we conducted a pilot implementation beginning in September
2006. The process involves pipeline surveillance, technology
assessment, review by an independent panel of clinical experts,
policy development and approval by an internal committee,
and policy implementation. Since Premera has a high quality
Pharmacy and Therapeutics Committee that meets the above
description, we utilized this group as an external review com-
mittee, adding one such technology review to each meeting
agenda.
Results: Between September 2006 and January 2008, 8 new
medical technologies were evaluated using this process and one
review was underway at the end of this period. Subjects of the
completed reviews consisted of 2 diagnostic scanning modalities,
2 genetic diagnostic tests, 1 other diagnostic modality, 1 robot-
assisted surgical procedure and 2 image-guided radiotherapy
procedures. Strength of evidence was generally unimpressive
with only 1 case having good evidence, 2 fair and 5 poor. Medical
policies were impacted by 6 reviews: medically necessary without
prior authorization (1), medically necessary with prior authori-
zation (1), investigational with certain exceptions (2) and inves-
tigational without exceptions (2). Payment policies were
established by 2 reviews, in each case determining that the new
procedure would be reimbursed at the same rate as its compara-
tor, since the published studies had failed to demonstrate addi-
tional incremental value.
Lessons Learned: Regional private payers can establish a
rigorous health technology assessment process incorporating
cost-effectiveness analysis, with modest assistance from health
outcomes faculty at a nearby university. These clinical and eco-
nomic evidence assessments are useful to create medical and
payment policies and to reﬁne existing policies. Having a rigor-
ous and transparent process strengthens credibility with provid-
ers and other external stakeholders. In addition, standardizing
processes for assessing value for medical products informs
manufacturers with regard to evidence expectations. Methodol-
ogy developed for reviewing pharmaceuticals can be adapted to
review non-pharmacologic entities, but lack of good quality
evidence from clinical trials is a serious limitation. Medical in-
novations delivering sufﬁcient high-quality evidence require a
comprehensive format to optimize opportunities for scientiﬁc
communication among payers, industry, and academia. Efforts to
establish higher evidence standards for devices and diagnostics
should be encouraged.
CASE 2
DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION
FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO
COMPREHENSIVE APPROACHTOTHE DIFFUSION OF
HEALTHTECHNOLOGIES
Levin L1, Goeree R2
1Ontario Ministry of Health and Long-Term Care,Toronto, ON,
Canada; 2McMaster University, Hamilton, ON, Canada
Organization: Ontario Ministry of Health and Long-Term Care
Program for the Assessment of Technologies in Health Research
Institute.
Problem or Issue Addressed: In 2002, the Ontario Ministry of
Health and Long-Term Care (MOHLTC) was advised that drug
eluting stent (DES) would present a diffusion pressure since
approximately 10,000 stents were being used per year and the
differential cost between bare metal stents (BMS) and DES was
$2200–$3840 per stent. An initial review of the literature by the
Medical Advisory Secretariat (MAS) found that in low-risk
patients the restenosis rates for BMS were 20–30% compared to
0–5% for DES. However, issues of generalisability to the Ontario
health system were raised in the MAS analysis, and a concern
that there would be creep to off-label use in high-risk patients.
Goals: Establish through a pragmatic study whether results pub-
lished from randomized controlled trials on DES are generalis-
able to Ontario and to use this as a basis for long-term funding
decision.
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